Clinical observation of paclitaxel liposome combined with nedaplatin in treatment of advanced esophageal cancer / 肿瘤

ABSTRACT

Objective: To evaluate the efficacy and toxicity of paclitaxel liposome combined with nedaplatin as first-line chemotherapy for patients with advanced esophageal cancer. Methods: A total of 42 patients with pathologically confirmed advanced esophageal cancer were recruited into this study. On day 1, the patients were intravenously infused with 135 mg/m2 paclitaxel liposome followed by nedaplatin 80 mg/m2. This chemotherapy regimen was repeated every three weeks until the documented disease progression, unacceptable toxicity or patients' refusal. All patients received at least two cycles of chemotherapy, and the short-term response and toxicity were evaluated every two cycles. The patients were followed-up, and the survival was analyzed. The intention-to-treat analysis was applied. Results: Forty-one of the 42 patients were assessable for short-term response. The overall response rate was 40.5% (17/42) including complete response in one patient (2.4%) and partial response in 16 patients (38.1%). Fourteen patients (33.3%) received stable disease, and ten patients received progressive disease (23.8%). The overall response rates of chemotherapy in naive patients (n =18) and relapsed patients (n=24) were 55.6% and 29.2%, respectively. The estimate of overall one-year survival rate was 42.6%. The median time to progression and the median overall survival time were 6.3 months and 11.3 months, respectively. The common adverse reaction was hematologic toxicity including 7 patients with grade 3/4 neutropenia and 4 patients with grade 3 thrombocytopenia. The main non-hematologic toxicity was grade 3/4 vomiting in 3 patients(7.3%). No toxicity-related death occurred. Conclusion: The combined therapy of paclitaxel liposome and nedaplatin is effective and well tolerated in patients with advanced esophageal cancer. Copyright© 2011 by TUMOR.